Prostate News and Research

RSS

Protein may hold key to restoring treatment response in drug-resistant neuroendocrine prostate cancer

It may be possible to restore drug-resistant neuroendocrine prostate cancer to a state that responds to treatment by depletion of a certain protein in cancer cells.

5 Feb 2024

PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

A team of researchers from the Badalona Applied Research Group in Oncology (B·ARGO) and the Urologic Tumours Unit of the Institut Català d'Oncologia (ICO) and the Germans Trias i Pujol Research Institute (IGTP) have found a new therapeutic strategy for patients with a specific subtype of metastatic prostate cancer resistant to standard chemotherapy treatment with docetaxel.

5 Feb 2024

Subcutaneous nivolumab revolutionizes renal cell carcinoma care with faster, easier treatment

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California.

29 Jan 2024

Overweight and obesity linked to rising death rates from bowel cancer among young adults

Overweight and obesity are contributing to rising death rates from bowel cancer among people aged 25-49 years in the European Union (EU) and the UK, although death rates from this type of cancer are decreasing overall across Europe.

29 Jan 2024

Research upends understanding of circadian clock in melanoma

A Ludwig Cancer Research study has found that the circadian clock-;which synchronizes physiological and cellular activities with the day-night cycle and is generally thought to be tumor suppressive-;in fact has a contextually variable role in cancer.

27 Jan 2024

New insights into why immunotherapy works for some cancers, not others

A multi-institutional study co-authored by University of Texas at Arlington scientists uncovered a mechanism by which cancer cells prevent the immune system from activating and attacking the cancerous invaders.

24 Jan 2024

Penn analysis shows low risk of secondary cancers following CAR T cell therapy

The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the University of Pennsylvania reported today in Nature Medicine.

24 Jan 2024

Combination drug therapy beats solo treatment for aggressive prostate cancer relapse

Combining testosterone-blocking drugs in patients with prostate cancer relapse prevents the spread of cancer better than treatment with a single drug, a multi-institution, Phase 3 clinical trial led by UC San Francisco researchers has found.

23 Jan 2024

Long-term prostate cancer treatment study informs decisions for diverse groups

A 10-year follow up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision making in terms of treatments and side effects for a diverse population.

23 Jan 2024

Team approach to prostate cancer: PCPs and urologists offer hope with active surveillance

This study considers the perspectives of primary care physicians (PCPs) and urologists on what facilitates and what creates barriers to active surveillance (AS) care for men with low-risk prostate cancer.

22 Jan 2024

Cancer drug holds promise for shrinking polycystic kidney cysts

Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function.

22 Jan 2024

Rutgers researchers devise strategy to boost prostate cancer treatment efficacy

Rutgers researchers can predict which patients will benefit from a popular prostate cancer drug – and have devised a strategy that may make the treatment work longer.

22 Jan 2024

Study evaluates factors associated with selection of active surveillance for low-risk prostate cancer

Because low-risk prostate cancer is unlikely to spread or impact survival, experts and guidelines recommend active surveillance, which involves regular monitoring and thus avoid or delay treatment like surgery or radiation therapy and their life-changing complications.

22 Jan 2024

Receptor protein found to be a key player in prostate cancer cells' drug resistance

Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells' resistance to docetaxel, a commonly used chemotherapy drug to treat advanced cancer that has spread beyond the prostate.

22 Jan 2024

UMass Amherst researcher aims to tackle bone damage in metastatic cancer

For some patients whose cancer has spread to their bones, the ensuing treatment can be more physically damaging than the original disease, leading to increased bone loss and fracture.

22 Jan 2024

Annexin-A1 targeted therapy beats several cancers

A new study published in Nature's cancer journal Oncogene highlights the effectiveness of MDX-124, the first therapeutic drug to target annexin-A1, a protein which is overexpressed in several cancer types and promotes tumour progression.

19 Jan 2024

New study challenges role of rectal exam in prostate cancer screening

A study by the Comprehensive Cancer Center Vienna of MedUni Vienna and Vienna General Hospital has taken a closer look at the effectiveness of common examination methods for the early detection of prostate cancer.

19 Jan 2024

Can yoga improve your prostate health?

The potential benefits of yoga in improving prostate health.

19 Jan 2024

Drinkable, carbon monoxide-infused foam supercharges cancer therapy

Did smokers do better than non-smokers in a clinical trial for an experimental cancer treatment? That was the intriguing question that led University of Iowa researchers and their colleagues to develop a drinkable, carbon monoxide-infused foam that boosted the effectiveness of the therapy, known as autophagy inhibition, in mice and human cells.

12 Jan 2024

Stromal cells may be useful in assessing prostate tumors' potential to spread

Non-cancerous cells called stromal cells, which are found in and around prostate tumors, may be useful in assessing these tumors' potential to spread, and may even be targets for future prostate cancer treatments, according to a study led by researchers at Weill Cornell Medicine.

12 Jan 2024

Prostate News and Research

Protein may hold key to restoring treatment response in drug-resistant neuroendocrine prostate cancer

PI3K/AKT and MEK/ERK pathways targeted in new therapy for docetaxel-resistant prostate cancer

Subcutaneous nivolumab revolutionizes renal cell carcinoma care with faster, easier treatment

Overweight and obesity linked to rising death rates from bowel cancer among young adults

Research upends understanding of circadian clock in melanoma

New insights into why immunotherapy works for some cancers, not others

Penn analysis shows low risk of secondary cancers following CAR T cell therapy

Combination drug therapy beats solo treatment for aggressive prostate cancer relapse

Long-term prostate cancer treatment study informs decisions for diverse groups

Team approach to prostate cancer: PCPs and urologists offer hope with active surveillance

Cancer drug holds promise for shrinking polycystic kidney cysts

Rutgers researchers devise strategy to boost prostate cancer treatment efficacy

Study evaluates factors associated with selection of active surveillance for low-risk prostate cancer

Receptor protein found to be a key player in prostate cancer cells' drug resistance

UMass Amherst researcher aims to tackle bone damage in metastatic cancer

Annexin-A1 targeted therapy beats several cancers

New study challenges role of rectal exam in prostate cancer screening

Can yoga improve your prostate health?

Drinkable, carbon monoxide-infused foam supercharges cancer therapy

Stromal cells may be useful in assessing prostate tumors' potential to spread

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News